Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
AlloVir
company
About
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $126.60M
- Industries
- Biotechnology,Clinical Trials,Pharmaceutical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 101 - 250
- Operating Status
- Active
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.
The company was founded in 2013 and headquartered in Houston, Texas.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$126.60M
AlloVir has raised a total of
$126.60M
in funding over 2 rounds. Their latest funding was raised on
Jul 27, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 27, 2022 | Post-IPO Equity | $126.60M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
AlloVir is funded by 1 investors.
Kite Pharma
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Kite Pharma
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
